Biocon Limited: Final Dividend for FY26 & TDS Communication
Biocon Limited recommended a final dividend of 10% (₹0.50 per share) for FY26, subject to shareholder approval at the AGM on August 06, 2026. The Record Date is July 03, 2026. The company detailed TDS regulations for resident and non-resident shareholders, requiring document submission by July 20, 2026.
The announcement concerns dividend distribution and tax implications, which are important for shareholders. The detailed procedural information and deadlines impact shareholder actions and understanding of dividend payouts.
The announcement is primarily informational, detailing the process and requirements for TDS on dividends. It does not contain any information that would significantly improve or harm the company's financial outlook or market position.
Biocon Limited has issued a communication to its shareholders regarding the deduction of tax at source (TDS) on the final dividend for the Financial Year 2025-26. The Board of Directors, in a meeting held on May 07, 2026, recommended a final dividend of 10%, amounting to ₹0.50 per equity share of face value ₹5. This dividend is subject to shareholder approval at the 48th Annual General Meeting (AGM) scheduled for August 06, 2026. The Record Date for determining eligible shareholders is July 03, 2026.
The company has detailed the applicable TDS rates and requirements for both resident and non-resident shareholders. For resident shareholders, TDS rates vary from Nil to 20% based on shareholder category, income thresholds, and submitted documentation such as self-declarations and Form 121. For non-resident shareholders, TDS rates are 10% or 20% plus applicable surcharge and cess, with options to avail benefits under Double Taxation Avoidance Agreements (DTAA) upon submission of specific documents like a Tax Residency Certificate (TRC) and a self-declaration.
Shareholders are urged to update their bank account details and PAN information with their Depository Participants or the Company's Registrar and Transfer Agent, KFin Technologies Limited. All necessary documents, including certificates and declarations, must be uploaded via a provided link or sent to the RTA by July 20, 2026. The company emphasizes that incomplete or improperly submitted documentation may lead to TDS deduction at higher rates, and any tax demands arising from inaccurate information will be the shareholder's responsibility.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.